We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $5.12B
1-Year Est. Return 314.02%
This Fund
S&P 500
This Quarter Est. Return
+30.91%
1 Year Est. Return
+314.02%
3 Year Est. Return
+1,498.66%
5 Year Est. Return
+2,457.67%
10 Year Est. Return
+48,821.41%
AUM
$1.29B
AUM Growth
+$94.4M
Cap. Flow
-$114M
Cap. Flow %
-8.85%
Top 10 Hldgs %
48.93%
Holding
207
New
56
Increased
31
Reduced
35
Closed
51

Top Buys

Rank Stock Value
1
IOVA icon
Iovance Biotherapeutics
IOVA
+$30.6M
2
QURE icon
uniQure
QURE
+$18.4M
3
NVRO
NEVRO CORP.
NVRO
+$16.5M
4
TVTX icon
Travere Therapeutics
TVTX
+$12.9M
5
ARAV
Aravive, Inc. Common Stock
ARAV
+$12M

Top Sells

Rank Stock Value
1
PTCT icon
PTC Therapeutics
PTCT
+$34.8M
2
RCPT
RECEPTOS INC COM STK (DE)
RCPT
+$21.8M
3
ESPR
Esperion Therapeutics
ESPR
+$19.5M
4
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$19.3M
5
TARO
Taro Pharmaceutical Industries Ltd.
TARO
+$18.5M

Sector Composition

Rank Sector Weight
1 Healthcare 79.95%
2 Technology 0.05%
3 Financials 0.04%
4 Energy 0.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FOLD
1
DELISTED
Amicus Therapeutics
FOLD
$157M 12.21%
14,439,444
– –
NBIX icon
2
Neurocrine Biosciences
NBIX
$18.2B
$149M 11.55%
3,741,267
+176,000
+5% +$6.3M
TVTX icon
3
Travere Therapeutics
TVTX
$5.13B
$66.7M 5.19%
2,784,980
+844,255
+44% +$12.9M
TSRO
4
DELISTED
TESARO, Inc.
TSRO
$56.2M 4.36%
978,359
+95,000
+11% +$4.48M
RLYP
5
DELISTED
RELYPSA INC COM
RLYP
$52.5M 4.08%
1,454,142
+215,000
+17% +$7.76M
IOVA icon
6
Iovance Biotherapeutics
IOVA
$2.02B
$32.9M 2.55%
+2,714,549
New +$30.6M
XNCR icon
7
Xencor
XNCR
$1.44B
$29.9M 2.33%
1,954,785
+27,614
+1% +$436K
DYAX
8
DELISTED
DYAX CORPORATION
DYAX
$29.8M 2.31%
1,777,000
-75,000
-4% -$1.17M
SRPT icon
9
Sarepta Therapeutics
SRPT
$1.65B
$29.3M 2.28%
2,204,652
-607,700
-22% -$8.1M
NVRO
10
DELISTED
NEVRO CORP.
NVRO
$26.7M 2.07%
557,056
+380,493
+215% +$16.5M
TLPH icon
11
Talphera
TLPH
$67M
$25.4M 1.97%
328,703
– –
QURE icon
12
uniQure
QURE
$2.77B
$25.2M 1.96%
1,039,332
+843,476
+431% +$18.4M
BLCM
13
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$24.2M 1.88%
104,640
– –
ARAV
14
DELISTED
Aravive, Inc. Common Stock
ARAV
$24.2M 1.88%
257,745
+102,550
+66% +$12M
ZBH icon
15
Zimmer Biomet
ZBH
$18.7B
$21.2M 1.65%
186,217
+27,501
+17% +$3.14M
CEMP
16
DELISTED
Cempra, Inc.
CEMP
$19.6M 1.53%
572,500
+325,000
+131% +$9.77M
RCPT
17
DELISTED
RECEPTOS INC COM STK (DE)
RCPT
$19.6M 1.52%
118,794
-172,600
-59% -$21.8M
ACAD icon
18
Acadia Pharmaceuticals
ACAD
$4.46B
$19.6M 1.52%
600,240
-493,041
-45% -$16.9M
ANIP icon
19
ANI Pharmaceuticals
ANIP
$1.85B
$19.3M 1.5%
307,784
-4,716
-2% -$287K
OTIC
20
DELISTED
Otonomy, Inc.
OTIC
$17M 1.32%
480,387
+26,081
+6% +$892K
BLUE
21
DELISTED
bluebird bio
BLUE
$16.3M 1.27%
10,422
-6,948
-40% -$9.17M
SNDA icon
22
Sonida Senior Living
SNDA
$1.96B
$15.7M 1.22%
40,333
+23,666
+142% +$8.7M
AGN
23
DELISTED
Allergan plc
AGN
$14.6M 1.14%
49,185
+34,097
+226% +$9.72M
PFNX
24
DELISTED
Pfenex Inc.
PFNX
$13.8M 1.07%
866,423
+461,758
+114% +$5.09M
PTLA
25
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$13.5M 1.05%
355,000
+330,000
+1,320% +$11.3M
1
2 3 4 5

Similar funds

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
TAM
Todd Asset Management Louisville, Kentucky $5.11B AUM 34.73% 1-Year Est. Return
CIA
Choate Investment Advisors Boston, Massachusetts $5.11B AUM 17.2% 1-Year Est. Return
AC
AKO Capital London, United Kingdom $5.11B AUM 2.56% 1-Year Est. Return
EIC
Equity Investment Corp Atlanta, Georgia $5.11B AUM 8.63% 1-Year Est. Return
CIC
Carnegie Investment Counsel Pepper Pike, Ohio $5.13B AUM 22.98% 1-Year Est. Return
CS
Cannell & Spears New York $5.1B AUM 31.77% 1-Year Est. Return
NC
Nicholas Company Milwaukee, Wisconsin $5.1B AUM 8.43% 1-Year Est. Return

Perceptive Advisors's Q1 2015 Portfolio in Review

As of Q1 2015, Perceptive Advisors held 207 positions worth $1.29B, up 7.9% from $1.19B the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Perceptive Advisors withdrew a net $114M in Q1 2015, closing 51 positions and reducing 35 holdings. Its most notable exit was PTC Therapeutics, an estimated $34.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 80% of assets, up from 77% a quarter earlier, followed by Technology and Financials.

Against the trend, Perceptive Advisors opened a new position in Iovance Biotherapeutics worth $32.9M.

  • Perceptive Advisors's largest Q1 2015 buy was Iovance Biotherapeutics: 2,714,549 shares worth $32.9M.
  • Perceptive Advisors added most to uniQure in Q1 2015, an estimated $18.4M increase.
  • Perceptive Advisors's biggest Q1 2015 reduction was RECEPTOS INC COM STK (DE), cutting an estimated $21.8M.
  • Perceptive Advisors fully exited PTC Therapeutics in Q1 2015, selling an estimated $34.8M.
  • Perceptive Advisors's ten largest holdings make up 49% of its $1.29B portfolio in Q1 2015.
  • Perceptive Advisors opened 56 new positions and closed 51 in Q1 2015.
  • Perceptive Advisors's portfolio value rose 7.9% quarter-over-quarter to $1.29B.

Based on Perceptive Advisors's 13F filing for Q1 2015, filed 15 May 2015.